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A bstract
The angiotensin converting enzym e (A C E) is a
strong candidate gene for m yocardial infarction
(M I). Insertion-deletion dim orphism in intron 16 of
this gene has been inconclusively found to be
associated w ith it. Several new polym orphism s in
the A C E gene have been identified and am ong
these, a dim orphism in exon 17, ACE G 2350A, has
a significant effect on plasm a A C E concentrations. To assess the value of genotyping the A C E
G 2350A dim orphism in a genetically hom ogeneous
population, w e carried out a case-control study of
dim orphism G 2350A for a putative association
w ith M I am ong Pakistani nationals. W e investigated a sam ple population of 370 Pakistanis,
com prising 163 controls, and 207 patients w ith
clinical diagnosis of acute M I (A M I). A C E G 2350A
alleles w ere visualized by assays based on polym erase chain reaction and restriction endonu clease analysis. Frequencies of G alleles w ere 0.68
am ong controls and 0.72 am ong AM I patients. The
A C E G 2350A dim orphism show ed no significant
2
association w ith M I (χ = 0.90, 2 df, P = 0.64),
plasm a levels of hom ocysteine (P = 0.52) or w ith

serum levels of folate (P = 0.299). The results indicate that A C E G 2350A polym orphism is not associated w ith risk of m yocardial infarction in the
P akistani population investigated here.
Keywords: angiotensin converting enzyme; folic acid;
genetics; homocysteine; myocardial infarction; Pakistani
population

In tro d u c tio n
Angiotensin converting enzyme (ACE) is a dipeptidyl
carboxypeptidase I, (EC. 3.4.15.1) that activates angiotensin I through cleavage of the carboxyterminal
dipeptide into the potent vasoconstrictor angiotensin
II and inactivates the vasodilator peptide bradykinin
(Erd ö s and Skidgel, 1987). Both are mediators of
vascular tone and smooth muscle cell proliferation
(Ehlers and Riordan, 1989). Experimental data suggest that the presence of high levels of plasma ACE
could result in the thickening of the vascular wall
eventually leading to the development of vascular
disease (Erd ö s and Skidgel, 1987; Ehlers and
Riordan, 1989).
Circulating ACE levels show extensive inter- individual variability and are highly genetically determined (Cambian et al., 1988; Alhenc-Gelas et al.,
1991). An insertion/deletion (I/D) dimorphism, due to
the presence or absence of a 287 base pair (bp)
alu-type sequence in intron 16 of the ACE gene, has
been shown to cosegregate with serum and tissue
ACE activities, and major locus inheritance explains
best the findings that the D allele is associated with
elevated ACE levels (Cambian et al., 1988; Rigat et
al., 1990; Alhenc-Gelas et al., 1991). Thus, the ACE
gene is viewed as a quantitative trait locus (QTL) that
modulates circulating ACE levels, and the ACE I/D
dimorphism is a marker that is thought to be in linkage disequilibrium (LD) with functional variants located in the ACE gene (Cambian et al., 1992; Tiret et
al., 1992; Arca et al., 1998) that are implicated in
CVDs.
Several studies on the association of ACE I/D
polymorphism and the risk for myocardial infarction
(MI) (Bohn et al., 1993; Cambien et al., 1994; Evans
et al., 1994; Soubrier and Cambien, 1994; Cambian
and Evans, 1995; Lindpainter et al., 1995; Villard and
Soubrier, 1996; Ferrieres et al., 1999; O’ Mally et al.,
1999; Keavney et al., 2000), have generated incon-
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sistent information. This has stimulated a search for
new polymorphisms in the ACE gene to identify better
markers or actual functional variants. Accumulated
evidence points to the existence of two QTLs at this
chromosomal locus (McKenzie et al., 1995; Villard et
al., 1996; Zhu et al., 2000; McKenzie et al., 2001).
A genome-scan analysis by The Framingham Heart
Study found strong evidence for a QTL on chromosome 17, located close to the ACE gene and
linked to blood pressure (Levy et al., 2000). Amongst
the 13 polymorphisms of the ACE gene recently
reported, a dimorphism in exon 17, ACE G2350A, has
the most significant effect on plasma ACE concentrations (Zhu et al., 2001). After adjustment for the
effect of ACE G2350A dimorphism, the I/D dimorphism was no longer associated with ACE, indicating
that it is in LD with ACE G2350A and unlikely to be
a functional mutation (Zhu et al., 2001).
To assess the value of genotyping of ACE in Pakistani population, we carried out a case-control study
of dimorphism G2350A for a putative association with
MI and with plasma/serum levels of homocysteine and
folate amongst Pakistani nationals. Our study is aimed
at establishing whether the ACE G2350A dimorphism
is a genetic marker and an independent risk factor
for MI.

M a terials a n d M eth o d s
Study subjects
Two hundred and seven consecutive Pakistani patients with acute MI (AMI) (age, 30-70 years) admitted
to the National Institute of Cardiovascular Diseases
(NICVD), Karachi from January 2001 to June 2001,
were selected for this study. They had confirmed
diagnosis of AMI on the basis of clinical history, ECG
and biochemical data.
Similarly, 163 normal healthy subjects who had
been matched for sex and to some extent for age
and belonged to the same socio-economic class,
were selected from the personnel of the Aga Khan
University and Civil Hospital, Karachi for this study.
Informed consent was obtained from the participants
and the study was approved by the Ethical Committee
of the Aga Khan University.
A stringent criteria was used for the selection of
normal healthy control subjects. In addition to being
matched for age, sex and socioeconomic background,
they had no evidence of CAD, diabetes mellitus, hypertension, obesity and hypercholesterolemia. Those
control subjects who were found to be pregnant,
using antiepileptics, oral contraceptives, having malabosorption syndrome, suffering from tuberculosis, uremia, liver disease, or using B-complex vitamins during
the last six months were excluded from this study.
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D N A analysis
Blood was collected in 10 m; Na-EDTA tubes and
kept frozen at -20 o C. DNA was extracted using standard protocols (Sambrook et al., 1989) and stored in
10 mM Tris-HCl, 1 mM EDTA, pH 8.0.
Codon 2350 ACE genotypes were first visualized
by a method based on allele-specific oligonucleotides
(McKenzie et al., 1995). It was then described as
ACE-8 by Zhu et al. (2001), as a modification by
introducing a mismatch guanine at the 3' end of the
primer sequence, resulting in the amplification of a
BstU1 restriction site. This more convenient method
involves a set of primers designed to amplify a
122-bp fragment encompassing the polymorphic region of ACE gene: 5'-CTGACGAATGTGATGGCCGC 3'
(upstream) and 5'-TTGATGAGTTCCACGTATTTCG-3'
(downstream). The PCR contained 100 to 200 ng
DNA template, 125 µ M dNTPs, 2.5 mM MgCl2 , and
0.3 mM of each primer and 1 U Taq polymerase, in
a final volume of 10 µl. After initial denaturation at
95 o C for 5 min, PCR was carried out for 35 cycles,
each one comprised of denaturation at 94 o C for 30
s, annealing at 58 oC for 30 s, and extension at 72 oC
for 30 s, with a final extension time of 10 min at 72 oC.
PCR products (5 µl) were digested with 5 U of BstUI
(Life Technologies) at 60 o C for 2 h. Digested fragments were separated by electrophoresis on 3%
agarose gel and identified by ethidium bromide staining. Allele G2350 was visualized as a 122-bp fragment and allele A2350 as 100-bp and 22-bp fragments.
D ata analysis
Statistical analyses were done with the help of an
SPSS Ⓡ version 10.0 for Windows Ⓡ software package
(Gorinchem, The Netherlands). Distribution differences
of G/A 2350 genotypes in the patients (AMI) as
compared to distribution in the control group as well
as Hardy-W einberg proportions of allele distribution
were assessed by chi-square analyses on 3×2
tables. Means were compared using ANOVA. For all
analyses, statistical significance was considered when
significance level (P) values were lower than 0.05.

R e su lts
Demographic and clinical characteristics of patients
have been listed in Table 1. The patient group
comprised 51 females and 156 males, showing a
female to male ration of 1:3. The mean age was 53±
9.6 years (range 30-70 years) in this group. Mean
body mass index (BMI) was 24±5.6, while mean
serum glucose concentration was 144±72 mg/dl.
Mean cholesterol concentration was 185±45 mg/dl.
43% of them were smokers, 31% were hypertensive,
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Table 1. Demographic and Clinical Characteristics of Subjects. (Mean±S.D)
ꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚ
Controls (n = 163)
Patients (n = 207)
ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ
ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ
Values
Frequency (%)
Values
Frequency (%)
ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ
Age (Years)
49.3±9.6
53±9.6
Gender (Male)
(Female)

123 (75.5)
40 (24.5)

156 (75.4)
51 (24.6)

Body mass index (kg/m 2 )

24.0±5.6

24.5±3.6

Glucose (mg/dl)

100±24

144±72*

Cholesterol (mg/dl)

168±34

185±45*

Smoking status (smokers)
(non-smokers)

17
83

43*
57

Diet (vegetarian)
(non-vegetarian)

3
97

1
99

Parental History of IHD (Yes)
(No)

15

26*
74

85

Hypertension (Yes)
(No)

0
100

31
69

Diabetes (Yes)
(No)

0
100

56
44

Homocysteine

17.8±7.7

17.8±8.2

Folate
5.33±3.44
3.33±3.81*
ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ
*Indicates a significant difference from the control values (P ＜ 0.05).
Table 2. Distribution of ACE G2350A genotypes and allele frequencies
(±standard errors) in the AMI patients and normal healthy subjects.
Percentage values of genotypes are indicated in parentheses.
ꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚ
AMI
Normal healthy
Genotype
(n = 207)
subjects (n = 163)
ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ
GG
110 (53)
85 (52)
GA
76 (37)
52 (32)
AA
p (G allele)

21 (10)

26 (16)

0.72±0.04

0.68±0.04

q (A allele)
0.28±0.04
0.32±0.04
ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ

57% were diabetic, while 19% were hypercholesterolemic. 26% of the patients had parental history of
ischemic heart disease (IHD).
Among the controls, the mean age was 49.3±9.6
years (range 31-70 years). There were 123 males and
40 females and the mean BMI for this group was 24
±5.6 which was quite close to the mean BMI of
cases. 17% of the controls were smokers. 15% of the
control subjects had parental history of IHD.
Table 2 shows the data pertaining to both genotype and allele distributions in the two groups of sub-

Table 3. Means (±S.D.) of age, BMI, plasma homocysteine and serum
folate values according to ACE G2350A dimorphism in the overall
sample population of this study.
ꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚ
GG
GA
AA
Variable
*P-value
(n = 195) (n = 128)
(n = 47)
ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ
Age (years)
50.1±9.4
50.7±8.9
51.5±8.9 0.609
BMI

24.3±4.4

24.5±4.3

23.6±3.9

0.471

Homocysteine
(µmol/l)

18.1±8.4

17.8±8.2

16.6±5.4

0.52

Folate (ng/ml)
3.93±3.6
3.84±3.1
4.71±3.3 0.2991
ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ
*P-value compares the mean values of the three genotypes for each
variable by oneway ANOVA.

jects. ACE genotypes did not occur in Hardy-W einberg proportions in the normal control group (χ2 =
5.82, 2 degrees of freedom (df), P = 0.054) nor in AMI
2
patients (χ = 0.90, 2 df, P = 0.64).
Differences in the distributions of the three genotypes
according to clinical phenotype were not statistically
2
significant (AMI vs Controls: χ = 3.1, 2 df, P = 0.217).
W e also sought to explore association of 2350 G
＞A genotypes (GG, GA, AA) with several phenotypic
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variables including age, BMI, serum folate and plasma
homocysteine. There was no significant difference
between the age and BMI profiles of the three genotypes (Table 3). The homocysteine and serum folate
values were also not statistically different between
genotypes (Table 3).

D iscu s sio n
Association (retrospective case-control) studies are
influenced by the effects of selection bias, population
stratification, confounding by other variables, and clinical criteria used to define patient groups. Minimizing the
influence of the first two variables can be achieved by
the exploration of putative associations in various ethnic
groups that may be more genetically homogenous.
Pakistani people belong to an ethnic group which
is relatively homogeneous and has the high rates of
coronary artery disease CAD (McKeigue et al., 1988).
Moreover, the relative risk of CAD in South Asian men
is the highest at early ages (Balerajan, 1991; McKeigue, 1992). This points to an increased genetic
predisposition of this population to the development
of CAD.
“Control” individuals that were included in this
investigation constituted a “comparison” rather than
a “control” group. They were indeed free of disease,
sex-matched with the patients, and had similar socioeconomic background to that of the patients. As these
control individuals had no evidence of MI, they represented a valid comparison group for these association
studies, though it could not be predicted whether
some of them would develop MI in future.
Several studies have suggested that the D allele
of ACE insertion/deletion (I/D) dimorphism confers
increased risk for CVD (Cambien et al., 1992; 1994;
Villard and Soubrier, 1996). At the same time, considerable negative evidence exists on this question. An
analysis of 11,000 cases and controls showed no
relationship between MI and the I/D polymorphism
(Evan et al., 1994). The I/D marker was likewise not
associated with MI in Italian and French sample
populations (Arca et al., 1998; Ferrieres et al., 1999).
O'Malley et al. (1999) summarized the association
between the I/D polymorphism and CVD risk, grouping studies by geographical region and disease
prevalence. In this analysis the ACE I/D polymorphism did not appear to be a clinically useful indicator
of risk for MI. Zhu et al. (2001) reported 13 polymorphisms in the ACE gene using linkage and association studies. The polymorphism in exon 17, ACE
G2350A had the most significant effect on plasma
ACE concentration, accounting for 19% of the total
variance in ACE plasma levels. After adjustment for
the effect of ACE G2350A dimorphism, the I/D poly-

113

morphism was no longer associated with plasma ACE
concentration, indicating that it is in LD with ACE
G2350A and unlikely to be a functional mutation.
Besides the effect on plasma ACE concentration, Zhu
et al. (2001) reported that this dimorphism was significantly associated with SBP with an average increase
of 3.2 mmHg with each copy of the G allele. These
observations were suggestive of a possible role of
ACE G2350A polymorphism in MI.
We report the allele frequency of the ACE G2350A
polymorphism in the Pakistani population to be 0.68±
0.04 and 0.32±0.04 for the G2350 and A2350 alleles
respectively. In the present study, G2350A genotype
distributions were not in Hardy-W einberg proportions
in the control group nor in the MI patient group. This
may be a direct effect of consanguinity in this
population.
Our data on the Pakistani population did not show
any significant association between G2350A polymorphism and MI. A recent study from our laboratory,
reported a significant association between G2350A
polymorphism and essential hypertension in Emirati
population (Mahmood et al., 2003), indicating that this
polymorphism may be the functional mutation of the
ACE gene. However, no association of G2350A polymorphism was found with MI in Emirati population.
Hyperhomocysteinemia has been an established risk
factor MI. A recent report by Westphal et al. indicated
that ACE inhibitors increase the plasma levels of
homocysteine in hypertensive patients, thereby compromising to some extent the cardio-protective function usually associated with them (2003). This was
also suggestive of a possible interaction between
ACE gene expression and plasma level of homocysteine. W hether a polymorphic change in the ACE
gene could have any influence on plasma homocysteine level is unknown, therefore, we investigated
whether there is any association between plasma
levels of homocysteine and ACE G2350A polymorphism. Although we found decreased levels of plasma
homocysteine in AA genotype (Table 3), the value
was not significantly different from the values in GG
and GA genotypes. This is suggestive of no association between any of the three genotypes and plasma
levels of homocysteine. Similarly, no association was
observed between any of these three genotypes and
serum folate levels.
In summary, our data support that the G2350A
dimorphism is neither associated with MI nor with
plasma homocysteine or folate in the Pakistani population. Given the complex nature of genetic susceptibility for chronic degenerative diseases, further studies need to be conducted in individual ethnic groups
to verify the disease relevance of this polymorphism.
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